State Street’s FibroBiologics FBLG Stock Holding History

State Street’s Portfolio FBLG Stock Details FBLG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-5,565	Closed	-$25K	–	4349
2025 Q4	$25K	Hold	5,565	–	–	﹤0.01%	4226
2025 Q3	$60.8K	Sell	5,565 -210	-4%	-$2.52K	﹤0.01%	4132
2025 Q2	$71.9K	Sell	5,775 -22,548	-80%	-$407K	﹤0.01%	4033
2025 Q1	$510K	Sell	28,323 -403	-1%	-$11.5K	﹤0.01%	3584
2024 Q4	$1.15M	Buy	28,726 +4,934	+21%	+$265K	﹤0.01%	3458
2024 Q3	$1.47M	Buy	23,792 +4,990	+27%	+$332K	﹤0.01%	3411
2024 Q2	$1.88M	Buy	+18,802	New	+$3.59M	﹤0.01%	3339

Other funds holding FBLG

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

FEG

Fund Evaluation Group Cincinnati, Ohio $3.7B AUM 16.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CFP

Cascade Financial Partners San Diego, California $1.15B AUM 33.6% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

NewEdge Advisors New Orleans, Louisiana $33.6B AUM 31.03% 1-Year Est. Return

Vanguard Global Advisers Malvern, Pennsylvania $215B AUM

State Street's FBLG Position: Q1 2026 in Review

State Street sold out of FibroBiologics (FBLG) in Q1 2026, closing a stake of 5,565 shares — an estimated $25K sold.

State Street first reported a position in FBLG in Q2 2024 and held it in 7 quarters. The position peaked at $1.88M in Q2 2024. 17 funds tracked by Wall St. Rank hold FBLG as of Q1 2026.

State Street reported no remaining FibroBiologics position as of Q1 2026 after selling out during the quarter.
State Street sold 5,565 FibroBiologics shares in Q1 2026, an estimated $25K.
State Street first reported a position in FibroBiologics in Q2 2024 and held it in 7 quarters.
State Street's FibroBiologics position peaked at $1.88M in Q2 2024.
17 funds tracked by Wall St. Rank held FibroBiologics as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.